Brigham and Women’s Hospital

LEO Science & Tech Hub, Brigham and Women’s Hospital collaborate

Thursday, June 15, 2017

LEO Science & Tech Hub announced a two-year collaboration with the Karp Lab at Brigham and Women’s Hospital (BWH) to develop minimally-invasive technology to advance dermal biomarker assessment. The Karp Lab, led by Jeffrey Karp, Ph.D., at BWH focuses on the development of platform technology and translational research to improve patient care. LEO Science & Tech Hub is an R&D innovation unit of LEO Pharma dedicated to identifying, developing, and funding innovative solutions that improve the lives of people with skin diseases.

[Read More]

The Institute for Protein Innovation launches

Friday, May 12, 2017

A team of scientists from the Massachusetts biomedical community launched a new research institute to expand protein science and enhance drug discovery. Backed by a unique and collaborative combination of public investment and academic philanthropy, The Institute for Protein Innovation (IPI) brings together leaders in academic research, biotechnology, pharmaceuticals and biomedical investing to seek new therapies for currently intractable diseases. 

[Read More]

Spotlight Innovation appoints Chitra Edwin SVP of Regulatory Affairs and Compliance

Thursday, December 8, 2016

Spotlight Innovation, a pharmaceutical company advancing technologies designed to address rare, emerging and neglected diseases, has announced the appointment of Chitra Edwin, Ph.D., RAC, as senior vice president of Regulatory Affairs and Compliance. Dr. Edwin will provide leadership for all U.S. and international regulatory matters including strategic planning for regulatory approvals, preparation of regulatory submissions, serving as the primary contact with the FDA and other regulatory authorities, and ensuring compliance with regulatory requirements.

[Read More]

Veristat appoints James Roach, M.D. as chief medical officer

Monday, November 7, 2016

Veristat has appointed James (Jim) Roach, M.D., FACP, FCCP as its new chief medical officer to bolster the expansion of its clinical operations, medical and regulatory affairs offerings. Dr. Roach will assume his position of chief medical officer on December 2, 2016. In this role, he will lead and grow the clinical operations, medical writing, medical monitoring, safety/pharmacovigilance and regulatory affairs teams at Veristat.

[Read More]

NIH funds additional medical centers for precision medicine research program

Monday, October 17, 2016

The NIH has announced awards to add four regional medical center groups to the national network of healthcare provider organizations (HPOs) that will implement the Precision Medicine Initiative (PMI) Cohort Program. Combined, the new HPOs will receive initial funds of $5.5 million to begin recruitment and build infrastructure. As efforts advance, the centers may receive first-year funds up to a total of $16 million. The four HPOs join awardees announced earlier this year, to enroll interested individuals, gather participants’ health information and biospecimens and provide input on developing plans for the program.

[Read More]

AHA, Verily, AstraZeneca announce One Brave Idea Research Award Winner

Tuesday, October 11, 2016

The American Heart Association (AHA), Verily Life Sciences (formerly Google Life Sciences), an Alphabet company, and AstraZeneca, have announced that the One Brave Idea research award will be granted to Dr. Calum MacRae, chief of Cardiovascular Medicine at Boston’s Brigham and Women’s Hospital, to support his visionary approach to understanding and addressing coronary heart disease (CHD) and its devastating consequences.

[Read More]

FDA’s proposed Expanded Access Navigator points to progress, not panacea

Monday, May 23, 2016

In response to the increasing demand for access to investigational drugs, creation of a clearinghouse to provide information on the request process has been proposed by the Reagan-Udall Foundation for the FDA. Dubbed the Expanded Access (EA) Navigator, the educational tool is the government’s latest effort to increase the efficiency of the complex process of requesting unapproved drugs outside of clinical trials for “compassionate use.”

[Read More]

Collaborative Cancer Cloud expands to drive medicines to patients faster

Monday, April 11, 2016

The Dana-Farber Cancer Institute (DFCI) of Boston and the Ontario Institute for Cancer Research (OICR) in Toronto have joined the Collaborative Cancer Cloud, a partnership formed in August 2015 by the Knight Cancer Institute at Oregon Health and Science University (OHSU) of Portland, Oregon, and Intel. By allowing research institutions to securely share genomic, imaging and clinical data on a precision medical analytics platform, the Collaborative Cancer Cloud is positioning itself to make rapid strides in cancer research and lifesaving therapies.

[Read More]